{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:47:33Z","timestamp":1790624853535,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848016011"],"award-info":[{"award-number":["848016011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"crossref","award":["W.OR17-03"],"award-info":[{"award-number":["W.OR17-03"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013560","name":"GBS\/CIDP Foundation International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GAIN UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>International guidelines recommend either intravenous immunoglobulin (IVIg) or corticosteroids as first-line treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). IVIg treatment usually leads to rapid improvement and is generally safe, but does not seem to lead to long-term remissions. Corticosteroids act more slowly and are associated with more side effects, but may induce long-term remissions. The hypothesis of this study is that combined IVIg and corticosteroid induction treatment will lead to more frequent long-term remissions than IVIg treatment alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An international, randomised, double-blind, placebo-controlled trial, in adults with \u2018probable\u2019 or \u2018definite\u2019 CIDP according to the EFNS\/PNS 2010 criteria. Three groups of patients are included: (1) treatment na\u00efve, (2) known CIDP patients with a relapse after &gt;\u20091\u2009year without treatment, and (3) patients with CIDP who improved within 3\u00a0months after a single course of IVIg, who subsequently deteriorate at any interval without having received additional treatment. Patients are randomised to receive 7 courses of IVIg and 1000\u2009mg intravenous methylprednisolone (IVMP) (in sodium chloride 0.9%) or IVIg and placebo (sodium chloride 0.9%), every 3\u2009weeks for 18\u2009weeks. IVIg treatment consists of a loading dose of 2\u2009g\/kg (over 3\u20135\u2009days) followed by 6 courses of IVIg 1\/g\/kg (over 1\u20132\u2009days). The primary outcome is remission at 1\u2009year, defined as improvement in disability from baseline, sustained between week 18 and week 52 without further treatment. Secondary outcomes include changes in disability, impairment, pain, fatigue, quality of life, care use and costs and (long-term) safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>In case of superiority of the combined treatment, patients will experience the advantages of two proven efficacious treatments, namely rapid improvement due to IVIg and long-term remission due to corticosteroids. Long-term remission would reduce the need for maintenance IVIg treatment and may decrease health care costs. Additionally, we expect that the combined treatment leads to a higher proportion of patients with improvement as some patients who do not respond to IVIg will respond to corticosteroids. Risks of short and long-term additional adverse events of the combined treatment need to be assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN registry <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN15893334\">ISRCTN15893334<\/jats:ext-link>. Prospectively registered on 12 February 2018.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05083-1","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T23:50:38Z","timestamp":1613865038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)"],"prefix":"10.1186","volume":"22","author":[{"name":"on behalf of the OPTIC study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-1362","authenticated-orcid":false,"given":"S. R. M.","family":"Bus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zambreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. A.","family":"Rajabally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D. M.","family":"Hadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. J. M.","family":"de Borgie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"issue":"5","key":"5083_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/jnnp.66.5.677","volume":"66","author":"MP Lunn","year":"1999","unstructured":"Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66(5):677\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"5083_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"EK Mathey","year":"2015","unstructured":"Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973\u201385.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"5083_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PY Van den Bergh","year":"2010","unstructured":"Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356\u201363.","journal-title":"Eur J Neurol"},{"key":"5083_CR4","volume":"12","author":"F Eftimov","year":"2013","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"5083_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","volume":"9","author":"IN van Schaik","year":"2010","unstructured":"van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245\u201353.","journal-title":"Lancet Neurol."},{"issue":"7","key":"5083_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneurol.2010.105","volume":"67","author":"N Latov","year":"2010","unstructured":"Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802\u20137.","journal-title":"Arch Neurol"},{"key":"5083_CR7","unstructured":"Eftimov F, van Schaik IN. De behandeling van chronische inflammatoire demyeliniserende polyradiculoneuropathie. Tijdschrift voor Neurologie en Neurochirurgie. 2012;113:237\u201344."},{"issue":"14","key":"5083_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/WNL.0b013e31824e8f84","volume":"78","author":"F Eftimov","year":"2012","unstructured":"Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012;78(14):1079\u201384.","journal-title":"Neurology."},{"issue":"6","key":"5083_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","volume":"11","author":"E Nobile-Orazio","year":"2012","unstructured":"Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493\u2013502.","journal-title":"Lancet Neurol"},{"issue":"3","key":"5083_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ene.14096","volume":"27","author":"ME Adrichem","year":"2019","unstructured":"Adrichem ME, Bus SR, Wieske L, Mohammed H, Verhamme C, Hadden R, et al. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Eur J Neurol. 2019;27(3):506\u201313.","journal-title":"Eur J Neurol."},{"key":"5083_CR11","volume-title":"Richtlijn Osteoporose en Fractuurpreventie. Derde herziening","author":"CBO","year":"2011","unstructured":"CBO. Richtlijn Osteoporose en Fractuurpreventie. Derde herziening 2011."},{"issue":"4","key":"5083_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76(4):337\u201345.","journal-title":"Neurology."},{"issue":"2","key":"5083_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RAC Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344.","journal-title":"Lancet Neurol"},{"issue":"11","key":"5083_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/jnnp.2009.194324","volume":"81","author":"IS Merkies","year":"2010","unstructured":"Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010;81(11):1194\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"5083_CR15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/ene.13025","volume":"23","author":"TH Draak","year":"2016","unstructured":"Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, et al. Correlation of the patient's reported outcome inflammatory-RODS with an objective metric in immune-mediated neuropathies. Eur J Neurol. 2016;23(7):1248\u201353.","journal-title":"Eur J Neurol"},{"issue":"23","key":"5083_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","volume":"83","author":"TH Draak","year":"2014","unstructured":"Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, et al. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology. 2014;83(23):2124\u201332.","journal-title":"Neurology."},{"issue":"2","key":"5083_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ana.1088","volume":"50","author":"R Hughes","year":"2001","unstructured":"Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50(2):195\u2013201.","journal-title":"Ann Neurol"},{"issue":"9","key":"5083_CR18","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O","volume":"23","author":"IS Merkies","year":"2000","unstructured":"Merkies IS, Schmitz PI, Samijn JP, Meche FG, Toyka KV, van Doorn PA. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve. 2000;23(9):1393\u2013401.","journal-title":"Muscle Nerve"},{"issue":"5","key":"5083_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","volume":"20","author":"EK Vanhoutte","year":"2013","unstructured":"Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol. 2013;20(5):748\u201355.","journal-title":"Eur J Neurol"},{"issue":"4","key":"5083_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1212\/WNL.54.4.943","volume":"54","author":"IS Merkies","year":"2000","unstructured":"Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology. 2000;54(4):943\u20139.","journal-title":"Neurology."},{"issue":"4","key":"5083_CR21","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","volume":"14","author":"SI van Nes","year":"2009","unstructured":"van Nes SI, Vanhoutte EK, Faber CG, Garssen M, van Doorn PA, Merkies IS, et al. Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale. J Peripher Nerv Syst. 2009;14(4):268\u201378.","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"5083_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.37.4.378","volume":"37","author":"WW Downie","year":"1978","unstructured":"Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5083_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"issue":"11","key":"5083_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve. 1991;14(11):1103\u20139.","journal-title":"Muscle Nerve"},{"issue":"3","key":"5083_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1017\/S0266462300009764","volume":"12","author":"L van Roijen","year":"1996","unstructured":"van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405\u201315.","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"5083_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","volume":"18","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van RL. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753\u20138.","journal-title":"Value Health"},{"issue":"23","key":"5083_CR27","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","volume":"19","author":"JA Barber","year":"2000","unstructured":"Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219\u201336.","journal-title":"Stat Med"},{"key":"5083_CR28","volume-title":"Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"L Hakkaart-van Roijen","year":"2015","unstructured":"Hakkaart-van Roijen L, VdLN, Bouwmans C, Kanters T, Tan SS. Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Rotterdam: Institute Medical Technology Assessment; 2015."},{"issue":"5","key":"5083_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336\u201347.","journal-title":"Value Health"},{"issue":"7","key":"5083_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","volume":"86","author":"E Nobile-Orazio","year":"2015","unstructured":"Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"5083_CR31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp-2014-309042","volume":"86","author":"K Kuitwaard","year":"2015","unstructured":"Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA. Intravenous immunoglobulin response in treatment-naive chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2015;86(12):1331\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5083_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35\u201346.","journal-title":"Lancet Neurol"},{"issue":"1","key":"5083_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jns.12303","volume":"24","author":"O Mielke","year":"2019","unstructured":"Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. J Peripher Nerv Syst. 2019;24(1):72\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"9404","key":"5083_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R van Koningsveld","year":"2004","unstructured":"van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363(9404):192\u20136.","journal-title":"Lancet."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-021-05083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T23:50:42Z","timestamp":1613865042000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5083"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05083-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"155"}}